These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22176279)

  • 1. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials.
    Maneeton N; Maneeton B; Srisurapanont M; Martin SD
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):611-7. PubMed ID: 22176279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
    Wilens TE; Haight BR; Horrigan JP; Hudziak JJ; Rosenthal NE; Connor DF; Hampton KD; Richard NE; Modell JG
    Biol Psychiatry; 2005 Apr; 57(7):793-801. PubMed ID: 15820237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.
    Maneeton B; Maneeton N; Likhitsathian S; Suttajit S; Narkpongphun A; Srisurapanont M; Woottiluk P
    Drug Des Devel Ther; 2015; 9():1927-36. PubMed ID: 25897203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
    Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV
    Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
    Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
    Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR; Haynes VS; Teicher MH; Newcorn JH
    Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.
    Maneeton N; Maneeton B; Suttajit S; Reungyos J; Srisurapanont M; Martin SD
    Drug Des Devel Ther; 2014; 8():1685-93. PubMed ID: 25336914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Maneeton N; Maneeton B; Intaprasert S; Woottiluk P
    Neuropsychiatr Dis Treat; 2014; 10():1439-49. PubMed ID: 25120365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
    Wilens TE; Spencer TJ; Biederman J; Girard K; Doyle R; Prince J; Polisner D; Solhkhah R; Comeau S; Monuteaux MC; Parekh A
    Am J Psychiatry; 2001 Feb; 158(2):282-8. PubMed ID: 11156812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion hydrochloride in attention deficit disorder with hyperactivity.
    Conners CK; Casat CD; Gualtieri CT; Weller E; Reader M; Reiss A; Weller RA; Khayrallah M; Ascher J
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1314-21. PubMed ID: 8885585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.